Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) released its earnings results on Wednesday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.
Odyssey Therapeutics Price Performance
Odyssey Therapeutics stock traded up $0.61 during midday trading on Wednesday, reaching $18.48. 471,192 shares of the stock traded hands, compared to its average volume of 330,129. Odyssey Therapeutics has a 12 month low of $15.35 and a 12 month high of $20.30.
Wall Street Analysts Forecast Growth
ODTX has been the subject of several research analyst reports. JPMorgan Chase & Co. assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price for the company. Cantor Fitzgerald assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating for the company. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. TD Cowen assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set a “buy” rating for the company. Finally, Oppenheimer assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $40.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.
Insiders Place Their Bets
In other news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $18.00, for a total value of $32,040.00. Following the completion of the sale, the insider directly owned 440,981 shares of the company’s stock, valued at $7,937,658. This trade represents a 0.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tpg Gp A, Llc acquired 1,388,889 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the purchase, the insider directly owned 3,690,146 shares in the company, valued at approximately $66,422,628. The trade was a 60.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 4,183,777 shares of company stock worth $75,319,986.
Featured Articles
- Five stocks we like better than Odyssey Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
